WC
CRNX icon

Wexford Capital’s Crinetics Pharmaceuticals CRNX Stock Holding History

Wexford Capital’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-3,080
Closed -$43K – 233
2020
Q4 		$43K Buy
+3,080
New +$42.9K 0.01% 200

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wexford Capital's CRNX Position: Q1 2021 in Review

Wexford Capital sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2021, closing a stake of 3,080 shares — an estimated $43K sold.

Wexford Capital first reported a position in CRNX in Q4 2020 and held it in 1 quarter. The position peaked at $43K in Q4 2020. 80 funds tracked by Wall St. Rank hold CRNX as of Q1 2021.

  • Wexford Capital reported no remaining Crinetics Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
  • Wexford Capital sold 3,080 Crinetics Pharmaceuticals shares in Q1 2021, an estimated $43K.
  • Wexford Capital first reported a position in Crinetics Pharmaceuticals in Q4 2020 and held it in 1 quarter.
  • Wexford Capital's Crinetics Pharmaceuticals position peaked at $43K in Q4 2020.
  • 80 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2021.

Based on Wexford Capital's 13F filing for Q1 2021, filed 13 May 2021.